Theraclion has received US FDA clearance to begin a new pivotal clinical trial testing the Sonovein® device for the treatment of primary insufficiency of great saphenous veins.
The multicenter study, called VEINRESET, will take place at four centers in the US and Europe.
Register for a Webinar | “Ablation” by Professor Sébastien Crouzet from the University Hospital of Lyon Edouard Herriot Hospital | June 15 at 11:00 am Eastern
“Alice was a person who made the world a better place. Every person and institution she touched was fortunate and better for her involvement.”
‒ Neal F. Kassell, MD
Manage Cookie Consent
We use cookies to optimize our website and our service.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
By using FUSF’s AI agent, you acknowledge and agree that your use is governed by FUSF’s Terms of Use Agreement. If you do not agree to be bound by the Terms of Use Agreement, you may not access or use FUSF’s AI agent.